Melissa Epperly

Insider Reports History

Entity
Individual
Location
C/O Zentalis Pharmaceuticals, Inc., 530 Seventh Avenue, Suite 2201, New York, NY
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Melissa Epperly
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Melissa Epperly:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Zentalis Pharmaceuticals, Inc. Chief Financial Officer Common Stock 451K $5.16M $11.44 Feb 12, 2024 Direct
Roivant Sciences Ltd. Director Common Shares 38K $443K $11.65 Oct 21, 2024 Direct
Zentalis Pharmaceuticals, Inc. Chief Financial Officer Stock Option (Right to Buy) 75K Feb 1, 2024 Direct
Nautilus Biotechnology, Inc. Director Stock Option (Right to Buy) 45K Jun 14, 2024 Direct
Roivant Sciences Ltd. Director Stock Option (Right to Buy) 27.9K Sep 10, 2024 Direct
Kinnate Biopharma Inc. Director Stock Option (right to buy) 0 Apr 3, 2024 Direct

Insider Reports Filed by Melissa Epperly

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ROIV Roivant Sciences Ltd. Oct 21, 2024 1 $0 4 Oct 23, 2024 Director
ROIV Roivant Sciences Ltd. Sep 12, 2024 1 -$51.4K 4 Sep 16, 2024 Director
ROIV Roivant Sciences Ltd. Sep 10, 2024 2 $0 4 Sep 12, 2024 Director
ROIV Roivant Sciences Ltd. Jul 23, 2024 1 $0 4 Jul 25, 2024 Director
NAUT Nautilus Biotechnology, Inc. Jun 14, 2024 1 $0 4 Jun 17, 2024 Director
ROIV Roivant Sciences Ltd. Apr 24, 2024 2 -$1.34K 4 Apr 26, 2024 Director
KNTE Kinnate Biopharma Inc. Apr 3, 2024 4 $0 4 Apr 5, 2024 Director
ZNTL Zentalis Pharmaceuticals, Inc. Feb 12, 2024 1 -$29.4K 4 Feb 12, 2024 Chief Financial Officer
ZNTL Zentalis Pharmaceuticals, Inc. Feb 1, 2024 3 -$100K 4 Feb 5, 2024 Chief Financial Officer
ROIV Roivant Sciences Ltd. Jan 19, 2024 1 $0 4 Jan 23, 2024 Director
ROIV Roivant Sciences Ltd. Oct 16, 2023 1 $0 4 Oct 18, 2023 Director
ZNTL Zentalis Pharmaceuticals, Inc. Oct 4, 2023 2 -$107K 4 Oct 6, 2023 Chief Financial Officer
ROIV Roivant Sciences Ltd. Sep 12, 2023 2 $0 4 Sep 14, 2023 Director
ROIV Roivant Sciences Ltd. Jul 3, 2023 1 $0 4 Jul 6, 2023 Director
NAUT Nautilus Biotechnology, Inc. Jun 15, 2023 1 $0 4 Jun 16, 2023 Director
KNTE Kinnate Biopharma Inc. Jun 12, 2023 1 $0 4 Jun 13, 2023 Director
ZNTL Zentalis Pharmaceuticals, Inc. Feb 13, 2023 2 -$158K 4 Feb 14, 2023 Chief Financial Officer
ZNTL Zentalis Pharmaceuticals, Inc. Feb 1, 2023 2 $0 4 Feb 1, 2023 Chief Financial Officer
ZNTL Zentalis Pharmaceuticals, Inc. Oct 3, 2022 1 $0 4 Oct 3, 2022 Chief Financial Officer
ROIV Roivant Sciences Ltd. Jul 20, 2022 1 $0 4 Jul 25, 2022 Director
ROIV Roivant Sciences Ltd. Jun 29, 2022 0 $0 3 Jul 11, 2022 Director
NAUT Nautilus Biotechnology, Inc. Jun 15, 2022 1 $0 4 Jun 16, 2022 Director
KNTE Kinnate Biopharma Inc. Jun 13, 2022 1 $0 4 Jun 15, 2022 Director
ZNTL Zentalis Pharmaceuticals, Inc. Apr 4, 2022 5 -$856K 4 Apr 5, 2022 Chief Financial Officer
ZNTL Zentalis Pharmaceuticals, Inc. Feb 23, 2022 2 -$93.9K 4 Feb 23, 2022 Chief Financial Officer
ZNTL Zentalis Pharmaceuticals, Inc. Feb 10, 2022 2 $0 4 Feb 14, 2022 Chief Financial Officer
ZNTL Zentalis Pharmaceuticals, Inc. Oct 2, 2021 1 -$1.15M 4 Oct 4, 2021 Chief Financial Officer
ZNTL Zentalis Pharmaceuticals, Inc. Aug 18, 2021 2 $500K 4 Aug 20, 2021 Chief Financial Officer
ZNTL Zentalis Pharmaceuticals, Inc. Jul 1, 2021 4 -$158K 4 Jul 6, 2021 Chief Financial Officer
KNTE Kinnate Biopharma Inc. Jun 11, 2021 1 $0 4 Jun 14, 2021 Director
NAUT Nautilus Biotechnology, Inc. Jun 9, 2021 0 $0 3 Jun 9, 2021 Director
ZNTL Zentalis Pharmaceuticals, Inc. Jun 1, 2021 2 -$167K 4 Jun 2, 2021 Chief Financial Officer